The PARITY Methods Centre team visited the Instituto de Ortopedia e Traumatologia da Universidade de São Paulo in Brazil earlier this week with the goal of completing the start-up phase and training the site personnel on the study’s operating procedures. While in São Paulo, the PARITY team also met with another Brazilian collaborator who has expressed an interest in participating in the trial to strategize a site specific plan for study initiation. There are now 34 sites open to enrolment across Canada, the United States, Australia, Argentina, South Africa and Brazil.
The PARITY trial is investigating whether long duration post-operative prophylactic antibiotics decreases the incidence of surgical site infections compared to the standard shorter duration among patients undergoing surgical excision and endoprosthetic reconstruction of lower extremity bone tumors. Led by Dr. Michelle Ghert, PARITY is the first rigorously designed trial in the field of orthopaedic oncology and has the potential to significantly impact clinical practice and establish a collaborative network worldwide for future research in the field. Prior to PARITY, orthopaedic oncologists doubted that prospective multi-center randomized trials were possible in their specialty. The success of the PARITY trial has demonstrated that these types of studies are, in fact, possible.